Premium
Adenosine: An endogenous mediator in the pathogenesis of gynecological cancer
Author(s) -
Bahreyni Amirhossein,
Samani Seyed S.,
Ghorbani Elnaz,
Rahmani Farzad,
khayami Reza,
Toroghian Younes,
BehnamRassouli Reihane,
Khazaei Majid,
Ryzhikov Mikhail,
Parizadeh Mohammad R.,
Hasanzadeh Malihe,
Avan Amir,
Hassanian Seyed M.
Publication year - 2018
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26056
Subject(s) - adenosine , adenosine receptor , purinergic signalling , angiogenesis , pathogenesis , cancer research , adenosine a3 receptor , mediator , cancer , medicine , metastasis , receptor , immunology , biology , agonist
Extracellular concentration of adenosine increases in the hypoxic tumor microenvironment. Adenosine signaling regulates apoptosis, angiogenesis, metastasis, and immune suppression in cancer cells. Adenosine‐induced cell responses depend upon different subtypes of adenosine receptors activation and type of cancer. Suppression of adenosine signaling via inhibition of adenosine receptors or adenosine generating enzymes including CD39 and CD73 on ovarian or cervical cancer cells is a potentially novel therapeutic approach for gynecological cancer patients. This review summarizes the role of adenosine in the pathogenesis of gynecological cancer for a better understanding and hence a better management of this disease.